Betta Pharmaceuticals (SHE:300558) received a drug registration certificate from China's National Medical Products Administration for ensartinib hydrochloride capsules, which trades as Bemena, according to a Shenzhen bourse disclosure published late Thursday.
The certificate is for the drug's indication as a treatment for patients with anaplastic lymphoma kinase-positive stage IB to stage IIIB non-small cell lung cancer who have previously undergone surgical resection.